Skip to main content

Advertisement

SpringerLink
Log in

Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment

  • Original Paper
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Topical pseudoceramides are successfully used in skin barrier repair therapy for atopic dermatitis (AD) and demonstrated to reduce the adverse effects of topical glucocorticoids (GC). However, the molecular mechanisms involved are not fully understood. We investigated whether PC-9S (myristoyl/palmitoyloxostearamide/arachamide MEA, Neopharm, Daejeon, Korea), one of the synthetic pseudoceramides, could stimulate peroxisome proliferator-activated receptor (PPAR)α expression in a hapten [oxazolone (oxa)]-induced AD murine model (oxa-AD mice) and subsequently improved permeability barrier, reduced inflammation, and increased antimicrobial peptides (AMPs) expression. Normal hairless mice and oxa-AD mice were topically treated twice daily with either PC-9S-containing physiologic lipid mixture (PLM), vehicle (PLM), or PPARα agonist for 4 days. Topical PC-9S significantly increased PPARα expression in mouse epidermis in vivo and in oxa-AD mice skin comparable with PPARα agonist. Topical PC-9S-containing PLM significantly reduced basal trans-epidermal water loss (TEWL), surface pH, and mast cell infiltrates and prevented the decline of AMPs expression in oxa-AD mice, which were abrogated by PPARα antagonist. Then, oxa-AD mice were treated with super-potent topical GC twice daily for 4 days with or without PC-9S co-applications. Co-treatment with PC-9S-containing PLM suppressed GC-induced increase in basal TEWL, epidermal thinning, reduced loricrin expression, and impaired barrier recovery and these effects were attenuated by PPARα antagonist. Collectively, our findings suggest that pseudoceramide PC-9S-induced stimulation of PPARα expression provides a new mechanism by which pseudoceramides show anti-inflammatory property, improve the permeability and antimicrobial barrier function, and prevent the negative effects of topical GC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Aberg KM, Man MQ, Gallo RL, Ganz T, Crumrine D, Brown BE, Choi EH, Kim DK, Schroder JM, Feingold KR, Elias PM (2008) Co-regulation and interdependence of the mammalian epidermal permeability and antimicrobial barriers. J Invest Dermatol 128:917–925

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Adachi Y, Hatano Y, Sakai T, Fujiwara S (2013) Expressions of peroxisome proliferator-activated receptors (PPARs) are directly influenced by permeability barrier abrogation and inflammatory cytokines and depressed PPARalpha modulates expressions of chemokines and epidermal differentiation-related molecules in keratinocytes. Exp Dermatol 22:606–608

    Article  CAS  PubMed  Google Scholar 

  3. Chamlin SL, Kao J, Frieden IJ, Sheu MY, Fowler AJ, Fluhr JW, Williams ML, Elias PM (2002) Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 47:198–208

    Article  PubMed  Google Scholar 

  4. Chiba T, Takeuchi S, Esaki H, Yamamura K, Kurihara Y, Moroi Y, Furue M (2012) Topical application of PPARalpha (but not beta/delta or gamma) suppresses atopic dermatitis in NC/Nga mice. Allergy 67:936–942

    Article  CAS  PubMed  Google Scholar 

  5. Dai X, Sayama K, Tohyama M, Shirakata Y, Hanakawa Y, Tokumaru S, Yang L, Hirakawa S, Hashimoto K (2010) PPARgamma mediates innate immunity by regulating the 1alpha,25-dihydroxyvitamin D3 induced hBD-3 and cathelicidin in human keratinocytes. J Dermatol Sci 60:179–186

    Article  CAS  PubMed  Google Scholar 

  6. de Koning HD, Kamsteeg M, Rodijk-Olthuis D, van Vlijmen-Willems IM, van Erp PE, Schalkwijk J, Zeeuwen PL (2011) Epidermal expression of host response genes upon skin barrier disruption in normal skin and uninvolved skin of psoriasis and atopic dermatitis patients. J Invest Dermatol 131:263–266

    Article  PubMed  Google Scholar 

  7. Demerjian M, Choi EH, Man MQ, Chang S, Elias PM, Feingold KR (2009) Activators of PPARs and LXR decrease the adverse effects of exogenous glucocorticoids on the epidermis. Exp Dermatol 18:643–649

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Draelos ZD (2008) The effect of ceramide-containing skin care products on eczema resolution duration. Cutis 81:87–91

    PubMed  Google Scholar 

  9. Geilen CC, Wieder T, Orfanos CE (1997) Ceramide signalling: regulatory role in cell proliferation, differentiation and apoptosis in human epidermis. Arch Dermatol Res 289:559–566

    Article  CAS  PubMed  Google Scholar 

  10. Hatano Y, Elias PM, Crumrine D, Feingold KR, Katagiri K, Fujiwara S (2011) Efficacy of combined peroxisome proliferator-activated receptor-alpha ligand and glucocorticoid therapy in a murine model of atopic dermatitis. J Invest Dermatol 131:1845–18452

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Hatano Y, Man MQ, Uchida Y, Crumrine D, Mauro TM, Feingold KR, Elias PM, Holleran WM (2010) Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol 125:160–169

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Imokawa G, Abe A, Jin K, Higaki Y, Kawashima M, Hidano A (1991) Decreased level of ceramides in stratum corneum of atopic dermatitis: an etiologic factor in atopic dry skin? J Invest Dermatol 96:523–526

    Article  CAS  PubMed  Google Scholar 

  13. Imokawa G, Akasaki S, Kawamata A, Yano S, Takaishi N (1989) Water-retaining function in the stratum-corneum and its recovery properties by synthetic pseudoceramides. J Soc Cosmet Chem 40:273–285

    CAS  Google Scholar 

  14. Imokawa G, Yada Y, Higuchi K, Okuda M, Ohashi Y, Kawamata A (1994) Pseudo-acylceramide with linoleic acid produces selective recovery of diminished cutaneous barrier function in essential fatty acid-deficient rats and has an inhibitory effect on epidermal hyperplasia. J Clin Invest 94:89–96

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Janssens M, van Smeden J, Gooris GS, Bras W, Portale G, Caspers PJ, Vreeken RJ, Kezic S, Lavrijsen AP, Bouwstra JA (2011) Lamellar lipid organization and ceramide composition in the stratum corneum of patients with atopic eczema. J Invest Dermatol 131:2136–2138

    Article  CAS  PubMed  Google Scholar 

  16. Jiang YJ, Uchida Y, Lu B, Kim P, Mao C, Akiyama M, Elias PM, Holleran WM, Grunfeld C, Feingold KR (2009) Ceramide stimulates ABCA12 expression via peroxisome proliferator-activated receptor delta in human keratinocytes. J Biol Chem 284:18942–18952

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Kang JS, Lee CW, Lee K, Han MH, Lee H, Youm JK, Jeong SK, Park BD, Han SB, Han G, Park SK, Kim HM (2008) Inhibition of skin inflammation and atopic dermatitis by topical application of a novel ceramide derivative, K112PC-5, in mice. Arch Pharm Res 31:1004–1009

    Article  CAS  PubMed  Google Scholar 

  18. Kang JS, Yoon WK, Youm JK, Jeong SK, Park BD, Han MH, Lee H, Moon EY, Han SB, Lee CW, Lee K, Park SK, Yang KH, Kim HM (2008) Inhibition of atopic dermatitis-like skin lesions by topical application of a novel ceramide derivative, K6PC-9p, in NC/Nga mice. Exp Dermatol 17:958–964

    Article  CAS  PubMed  Google Scholar 

  19. Kim HJ, Park HJ, Yun JN, Jeong SK, Ahn SK, Lee SH (2011) Pseudoceramide-containing physiological lipid mixture reduces adverse effects of topical steroids. Allergy Asthma Immunol Res 3:96–102

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  20. Lee HK, Nam GW, Kim SH, Lee SH (2006) Phytocomponents of triterpenoids, oleanolic acid and ursolic acid, regulated differently the processing of epidermal keratinocytes via PPAR-alpha pathway. Exp Dermatol 15:66–73

    Article  PubMed  Google Scholar 

  21. Lee YB, Park HJ, Kwon MJ, Jeong SK, Cho SH (2011) Beneficial effects of pseudoceramide-containing physiologic lipid mixture as a vehicle for topical steroids. Eur J Dermatol 21:710–716

    CAS  PubMed  Google Scholar 

  22. Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elias PM, Holleran WM, Feingold KR (2006) Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol 126:386–392

    Article  CAS  PubMed  Google Scholar 

  23. Man MQ, Hatano Y, Lee SH, Man M, Chang S, Feingold KR, Leung DY, Holleran W, Uchida Y, Elias PM (2008) Characterization of a hapten-induced, murine model with multiple features of atopic dermatitis: structural, immunologic, and biochemical changes following single versus multiple oxazolone challenges. J Invest Dermatol 128:79–86

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Moraes LA, Piqueras L, Bishop-Bailey D (2006) Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther 110:371–385

    Article  CAS  PubMed  Google Scholar 

  25. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, Darst MA, Gao B, Boguniewicz M, Travers JB, Leung DY (2003) Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol 171:3262–3269

    Article  CAS  PubMed  Google Scholar 

  26. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, Gallo RL, Leung DY (2002) Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347:1151–1160

    Article  CAS  PubMed  Google Scholar 

  27. Peyrin-Biroulet L, Beisner J, Wang G, Nuding S, Oommen ST, Kelly D, Parmentier-Decrucq E, Dessein R, Merour E, Chavatte P, Grandjean T, Bressenot A, Desreumaux P, Colombel JF, Desvergne B, Stange EF, Wehkamp J, Chamaillard M (2010) Peroxisome proliferator-activated receptor gamma activation is required for maintenance of innate antimicrobial immunity in the colon. Proc Natl Acad Sci USA 107:8772–8777

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Plager DA, Leontovich AA, Henke SA, Davis MD, McEvoy MT, Sciallis GF 2nd, Pittelkow MR (2007) Early cutaneous gene transcription changes in adult atopic dermatitis and potential clinical implications. Exp Dermatol 16:28–36

    Article  CAS  PubMed  Google Scholar 

  29. Sheu MY, Fowler AJ, Kao J, Schmuth M, Schoonjans K, Auwerx J, Fluhr JW, Man MQ, Elias PM, Feingold KR (2002) Topical peroxisome proliferator activated receptor-alpha activators reduce inflammation in irritant and allergic contact dermatitis models. J Invest Dermatol 118:94–101

    Article  CAS  PubMed  Google Scholar 

  30. Staumont-Salle D, Abboud G, Brenuchon C, Kanda A, Roumier T, Lavogiez C, Fleury S, Remy P, Papin JP, Bertrand-Michel J, Terce F, Staels B, Delaporte E, Capron M, Dombrowicz D (2008) Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 121:962–968

    Article  CAS  PubMed  Google Scholar 

  31. Tsuji K, Satoh S, Mitsutake S, Murakami I, Park JJ, Li Q, Chang YT, Chung SK, Igarashi Y (2009) Evaluation of synthetic sphingolipid analogs as ligands for peroxisome proliferator-activated receptors. Bioorg Med Chem Lett 19:1643–1646

    Article  CAS  PubMed  Google Scholar 

  32. Wiren K, Nohlgard C, Nyberg F, Holm L, Svensson M, Johannesson A, Wallberg P, Berne B, Edlund F, Loden M (2009) Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 23:1267–1272

    Article  CAS  PubMed  Google Scholar 

  33. Yoon NY, Jung MY, Kim DH, Lee HJ, Choi EH (2015) Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model. Arch Dermatol Res. doi:10.1007/s00403-015-1558-y

Download references

Conflict of interest

None declared.

Author information

Authors and Affiliations

  1. Department of Dermatology, Yonsei University College of Medicine, Gangnam Severance Hospital, 712 Eonjuro, Gangnam-gu, Seoul, 135-720, Korea

    Sang Eun Lee, Min Kyung Jung, Seung Joon Oh & Seung Hun Lee

  2. Research Division, Neopharm Co., Ltd, Daejeon, Korea

    Se Kyoo Jeong

Authors
  1. Sang Eun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Min Kyung Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Seung Joon Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Se Kyoo Jeong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Seung Hun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seung Hun Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, S.E., Jung, M.K., Oh, S.J. et al. Pseudoceramide stimulates peroxisome proliferator-activated receptor-α expression in a murine model of atopic dermatitis: molecular basis underlying the anti-inflammatory effect and the preventive effect against steroid-induced barrier impairment. Arch Dermatol Res 307, 781–792 (2015). https://doi.org/10.1007/s00403-015-1584-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-015-1584-9

Keywords

Search

Navigation